Skip to content
Open access

Chemopreventive Effect of Bitter Melon (Momordica charantia) Juice on Pancreatic Carcinogenesis in LSL‐KrasG12D /+; p48Cre/+ Mice

Aug 2026 · Molecular Carcinogenesis · Vol 65, pp. 1383 - 1397 · 0 citations · 55 references
Medicine

TL;DR

Results indicated that BMJ shifted the pancreatic tumor profile from moderately differentiated adenocarcinoma in controls towards a more heterogeneous profile enriched for well‐differentiated lesions indicating that prolonged exposure to BMJ bioactives results in a less aggressive phenotype.

Abstract

Herein, using the LSL‐KrasG12D/+; p48Cre/+ transgenic mouse model [that recapitulates the full spectrum of human disease, progressing from early pancreatic intraepithelial neoplasia lesions to invasive pancreatic ductal adenocarcinoma (PDAC)], we determined the chemopreventive effect of long‐term (chronic) administration of Bitter Melon Juice (BMJ‐standardized lyophilized juice processed from the fruits of Momordica charantia) against pancreatic cancer. Starting at 6 weeks of age, female LSL‐KrasG12D/+; p48Cre/+ mice were subjected to BMJ intervention (oral gavage, dose: 200 mg/kg body wt., 5 days/week) for 35 weeks (study end: 41 weeks of age), and pathological and molecular changes in the pancreas were assessed. Results indicated that BMJ shifted the pancreatic tumor profile from moderately differentiated adenocarcinoma in controls towards a more heterogeneous profile enriched for well‐differentiated lesions indicating that prolonged exposure to BMJ bioactives results in a less aggressive phenotype. BMJ significantly reduced proliferative index (~24%) and induced a ~ 4‐fold increase in apoptosis in the pancreas. The effects on AMPK activation (~2‐fold increase) and decrease in the expression of [glucose (GLUT‐1) and lactate (MCT‐4) transporter levels (∼49%–69%,), NF‐κB/p65 (~40%), EMT marker‐Vimentin (~46%), fibrotic microenvironment marker (α‐SMA, ~29%) and Mucin‐1 (MUC‐1, ~45%)] indicate that BMJ modulates several interconnected pathways essential for PDAC growth and progression. Plasma proteomic profiling indicated that Fractalkine (CX3CL1), MIP‐3β (CCL19), MIP‐3α (CCL20), and SCF were decreased by BMJ, while Axl and TNF‐alpha were overexpressed in BMJ‐treated animals compared to positive controls. These results encourage further research into bitter melon compounds as a potential chemopreventive option for pancreatic cancer, especially for high‐risk groups.

Read PDF

Similar papers

Oct 2026

A modified 4NQO-induced oral carcinogenesis model defines a chemopreventive intervention window and reveals progression-modulatory effects of black tea polyphenols.

The modified 4NQO model provides a robust platform for stage-specific chemoprevention evaluation, with black tea polyphenols, particularly decaffeinated extracts, demonstrating modest progression-modulating effects that warrant further investigation.

Sakshi S. Anchan, Pooja S. Kohinkar, Yadnyesh G. Bhandari et al. · 0 citations
Open access Sep 2026

Epigallocatechin-3-Gallate, the green tea polyphenol suppresses expression of CD31 and VEGFR2 and enhances the chemotherapeutic potential of irinotecan in AOM/DSS model of colorectal cancer in mice

Conventional chemotherapeutic treatment of colorectal cancer causes adverse effects such as severe diarrhoea, mucositis and hepatotoxicity. This study aimed to investigate the anti-carcinogenic potential of epigallocatechin-3-gallate and its effects on major angiogenic markers, alone and in combination with irinotecan...

Sabana Rahman, Sukanya Baruah, Nabila Akhtara et al. · 0 citations
Oct 2026

Enhanced hepatoprotective effect of Phoenix dactylifera L. and carvedilol in dexamethasone-induced toxicity in rats by reducing oxidative stress and apoptosis: possible role of Hotair-1/mir-148a pathway.

BACKGROUND Corticosteroid toxicity can predispose individuals to metabolic dysfunction-associated steatotic liver disease (MASLD), which may progress to metabolic dysfunction-associated steatohepatitis (MASH). Date palm fruit (Phoenix dactylifera L.) is widely recognized as a nutraceutical due to its rich content of bi...

Rasha M. S. M. Mohamed, N. H. Hassan, Sherein F. El-sayed et al. · 0 citations
Sep 2026

Abstract A128: Design of a Phase 2 basket trial to assess mifomelatide (TCMCB07) in GI cancer cachexia: A focus on pancreatic ductal adenocarcinoma (PDAC)

Background: Cachexia is common in gastrointestinal (GI) cancers in general and pancreatic ductal adenocarcinoma (PDAC) in particular. PDAC has one of the highest prevalences and earliest onsets of cancer cachexia, affecting up to 90% of patients. Furthermore, the extent of weight lost among patients with PDAC exceeds...

M. Joly, W. Riedl, W. Grant et al. · 0 citations
Open access 2021

A long term study to unravel the chemopreventive efficacy of pMethoxycinnamic acid in comparison to sorafenib, a standard drug against NDEA induced hepatocarcinogenesis

Results established that supplementation with p-MCA and the reference drug (sorafenib) to NDEA induced rats significantly decreased the incidence of cancer in the liver, besides altering the phase I and phase II xenobiotic enzymes.

Sriragavi Ravi, Rajagopal Ayyanar, N. Namasivayam · 2 citations
Open access Oct 2026

Ursolic acid sensitizes hepatoma cells to sulfasalazine-induced ferroptosis via AMPK/BECN1/SLC7A11-mediated redox disruption in vitro and in vivo

Targeting ferroptosis has emerged as a promising anti-cancer strategy. A Food and Drug Administration (FDA)-approved drug, sulfasalazine (SAS), also a ferroptosis inducer, is being explored as a potential treatment drug for cancer. However, long-term high-dose SAS treatment may induce several adverse effects in the...

Kai Han, Jia-Yuan Li, Bing-Ying Shuai et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.